Literature DB >> 2993207

Increased frequency of IgG heavy chain marker Glm(2) and of HLA-B8 in Lambert-Eaton myasthenic syndrome with and without associated lung carcinoma.

N Willcox, A G Demaine, J Newsom-Davis, K I Welsh, S A Robb, S G Spiro.   

Abstract

In view of the evidence for an autoimmune pathogenesis of the Lambert-Eaton myasthenic syndrome, we have sought associations with IgG heavy chain allotypes (Gm) and HLA antigens in 30 patients, of whom 20 had evidence of lung carcinoma (histologically proven small ("oat") cell type in 17). A highly significant overall increase in frequency of Glm(2) (chi 2 = 10.95; p less than 0.001; n = 30) and of HLA-B8 (chi 2 = 19.07; p less than 0.001; n = 23) was observed. These two factors apparently occurred independently of each other. The Glm(2) frequency in 36 non-myasthenic small cell carcinoma cases was the same as in a control panel (n = 167). We conclude that Glm(2) and HLA-B8 both associate with increased susceptibility to the Lambert-Eaton myasthenic syndrome, and suggest that Glm(2) may be in linkage disequilibrium with a limited number of VH genes coding for antibodies to restricted antigenic determinants at the nerve terminals, which may be shared by the carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2993207     DOI: 10.1016/0198-8859(85)90062-x

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  11 in total

Review 1.  Gm allotype system and autoimmune diseases.

Authors:  M Abu-Shakra; Y Shoenfeld
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome.

Authors:  J P Heath; D J Ewing; R E Cull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

Review 3.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

4.  Susceptibility to multiple sclerosis associated with an immunoglobulin gamma 3 restriction fragment length polymorphism.

Authors:  C N Gaiser; M J Johnson; G de Lange; L Rassenti; L L Cavalli-Sforza; L Steinman
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

Review 5.  Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1985

Review 6.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

7.  Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients.

Authors:  J Newsom-Davis; K Leys; A Vincent; I Ferguson; G Modi; K Mills
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

8.  Immunoglobulin heavy chain switch region restriction fragment length polymorphisms are associated with renal disease.

Authors:  A G Demaine; D H Taube; R W Vaughan; L A Kerr; K I Welsh
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

9.  Immunocytochemical characteristics of small cell lung carcinoma associated with the Lambert-Eaton myasthenic syndrome.

Authors:  C S Morris; M M Esiri; A Marx; J Newsom-Davis
Journal:  Am J Pathol       Date:  1992-04       Impact factor: 4.307

Review 10.  Immunopathology of the Lambert-Eaton myasthenic syndrome.

Authors:  B Lang; J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.